Structured smoking cessation programmes combining behavioural counselling, nicotine replacement therapy, and post-discharge support during inpatient psychiatric treatment may successfully increase tobacco quit rates at six months. Evaluated across global clinical trials, integrating these interventions addresses the severe physical health disparities faced by individuals with mental illness.
People receiving treatment in hospital for psychiatric conditions face a stark epidemiological reality. Individuals experiencing severe mental illness die up to 15 to 20 years earlier than the general population, predominantly driven by preventable physical conditions such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes, and malignancies. Tobacco smoking remains a primary vector for these morbidities. Despite high motivation to quit, inpatients smoke at rates significantly higher than the general public and historically experience lower cessation success.
In response to this persistent public health challenge, a systematic evaluation updated recently assessed whether implementing structured smoking cessation programmes within hospital psychiatric wards can effectively bridge this gap. Authored within the Cochrane Database of Systematic Reviews, the comprehensive synthesis investigates clinical outcomes for adult patients undergoing acute or long-stay psychiatric care.
In Plain English: The Clinical Takeaway
- Comprehensive Support Wins: Combining face-to-face counselling with nicotine replacement therapy (NRT) during a hospital stay—and continuing that support after discharge—helps more patients stay smoke-free at six months.
- The Marginal Gain: Current clinical evidence indicates that structured inpatient-to-outpatient support programmes may help about 6 more people per 100 successfully quit smoking compared to standard hospital care.
- Evidence Gaps Remain: While pharmaceuticals like varenicline are effective in community settings, robust clinical trials testing various anti-smoking medicines specifically inside psychiatric inpatient facilities are still urgently needed.
Evaluating the Clinical Trial Data
The review identified 10 randomized controlled studies encompassing a total of 2,262 participants across emergency and long-stay psychiatric wards in five countries: Australia, the United States, Taiwan, Israel, and Iran. The diagnostic profiles of participants varied widely, covering mood disorders, anxiety disorders, and schizophrenia spectrum illnesses across three focused studies.
The analyzed interventions primarily investigated behavioural counselling paired with nicotine replacement therapy—a pharmacological intervention supplying therapeutic nicotine via patches, gums, or lozenges to mitigate withdrawal symptoms and metabolic cravings—alongside sustained post-discharge tracking. Secondary arms explored group behavioural interventions without pharmacotherapy, comparisons of varying NRT dosages, and specific medications like bupropion versus a placebo or cytisine versus NRT.
Meta-analytic pooling of five studies involving 1,611 participants demonstrated that the combined intervention of counselling, nicotine replacement therapy, and post-discharge continuity may increase biochemically verified or self-reported smoking abstinence at six months by approximately 6 additional quitters per 100 patients. Data regarding severe adverse events, including all-cause mortality, suggested potential reductions in mortality (1 fewer death per 100 people), though authors assigned this specific metric a low certainty rating due to low overall event rates.
Global Regulatory Context and Healthcare Systems
Contraindications & When to Consult a Doctor
While smoking cessation is universally beneficial for long-term health, implementing pharmacotherapy in an acute psychiatric setting requires meticulous clinical oversight. Nicotine replacement therapy is contraindicated in patients experiencing acute myocardial infarction, severe arrhythmias, or unstable angina without direct medical clearance.
Furthermore, abrupt smoking cessation can alter the hepatic metabolism of certain psychotropic medications—particularly antipsychotics like clozapine and olanzapine—via the induction of cytochrome P450 enzyme pathways (specifically CYP1A2). When a patient stops smoking, blood serum concentrations of these medications can rise sharply, potentially triggering drug toxicity.
The Future of Inpatient Cessation Pathways
While current evidence confirms a modest yet meaningful benefit from combined counselling and NRT, the medical community underscores the necessity for larger, rigorously designed clinical trials exploring varied pharmacotherapies in vulnerable populations.
References
- Cochrane Database of Systematic Reviews. Programmes for quitting smoking for people in hospital for treatment of mental illness. Updated February 2026.
- World Health Organization (WHO). Tobacco and mental health: a critical review of public health data.
- Smoking cessation: acute, maternity and mental health services.
- Substance Abuse and Mental Health Services Administration (SAMHSA). Implementing tobacco cessation policies in psychiatric facilities.
Disclaimer: This article is for informational purposes only and does not constitute formal medical advice, diagnosis, or treatment. Always consult a qualified physician or mental health professional regarding specific clinical protocols and medication adjustments.
